Key Takeaways Reliance on large pharma clients and high R&D outlays limit revenue growth and keep earnings negative despite new product initiatives and expanding collaborations. Intensifying competition, slow adoption by new customers, and regulatory uncertainties challenge sustained pricing power and margin improvement.Read more
Key Takeaways Accelerating adoption of AI-powered software, cloud solutions, and regulatory engagement could drive substantial growth in both revenue and market reach. Strategic positioning in precision medicine and expanding collaborations position the company for sustained earnings growth and outsized industry influence.Read more
Key Takeaways Advancements in clinical programs and strategic partnerships position the company for long-term revenue growth and improved earnings visibility. Increasing demand and improvements in AI-driven software drive higher market penetration, recurring SaaS revenues, and stronger operating margins.Read more
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
